In summary, the convergence of natural products, target-specific therapeutic strategies, and network pharmacology represents a promising direction in liver injury drug development. By addressing current limitations and harnessing emerging technologies, future research has the potential to fully realize the therapeutic value of these integrated approaches, ultimately advancing the development of more effective and personalized treatments for liver diseases.
Li et al. (Sun,) studied this question.